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Antihypertensive and antiproteinuric efficacy of ramipril in
children with chronic renal failure.
Background. While the antihypertensive and renoprotective
potency of angiotensin-converting enzyme (ACE) inhibitors is
well-established in adults with hypertension and/or chronic re-
nal failure, little experience exists in pediatric chronic kidney
disease.
Methods. As part of a prospective assessment of the reno-
protective efficacy of ACE inhibition and intensified blood
pressure (BP) control, 397 children (ages 3 to 18 years) with
chronic renal failure [CRF; glomerular filtration rate (GFR) 11
to 80 mL/min/1.73 m2] and elevated or high-normal BP received
ramipril (6 mg/m2) following a 6-month run-in period including
a two-month washout of any previous ACE inhibitors. Drug ef-
ficacy was assessed by two monthly office BP and proteinuria
assessments, and by ambulatory BP monitoring at start and after
6 months of treatment.
Results. In the 352 patients completing six months of treat-
ment, 24-hour mean arterial pressure (MAP) had decreased
by a mean of 11.5 mm Hg (−2.2 SDS) in initially hypertensive
subjects, but only by 4.4 mm Hg (−0.8 SDS) in patients with ini-
tially normal BP. A linear correlation was found between MAP
at baseline and the change of MAP during treatment (r = 0.51;
P < 0.0001). The antihypertensive response was independent
of changes in concomitant antihypertensive medication or un-
derlying renal disease. BP was reduced with equal efficacy dur-
ing day- and nighttime. Urinary protein excretion was reduced
by 50% on average, with similar relative efficacy in patients
with hypo/dysplastic nephropathies and glomerulopathies. The
magnitude of proteinuria reduction depended on baseline pro-
teinuria (r = 0.32, P < 0.0001), and was correlated with the
antihypertensive efficacy of the drug (r = 0.22, P < 0.001). The
incidence of rapid rises in serum creatinine and progression
to end-stage CRF during treatment did not differ from the pre-
treatment observation period. Mean serum potassium increased
by 0.3 mmol/L. Ramipril was discontinued in three patients due
1Participants of the ESCAPE (Effect of Strict Blood Pressure Control
and ACE Inhibition on CRF Progression in Pediatric Patients) Trial
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to symptomatic hypotension or hyperkalemia. Hemoglobin lev-
els decreased by 0.6 g/dL in the first two treatment months and
remained stable thereafter.
Conclusion. Ramipril appears to be an effective and safe an-
tihypertensive and antiproteinuric agent in children with CRF-
associated hypertension. The BP lowering and antiproteinuric
effects are greatest in severely hypertensive and proteinuric
children.
Most antihypertensive agents currently used in chil-
dren are administered off label. Historically, explicit ap-
proval for pediatric use has usually not been applied for
by the manufacturers because clinical studies in children
are more demanding than trials in adult patients with
respect to various ethical, biometrical, and practical is-
sues. Only recently, the Best Drugs for Children Act in
the U.S., and similar activities in Europe, have cleared
the way for appropriate clinical trials to investigate the
pharmacokinetic, dose-effect, and safety properties of in-
dividual drugs in children.
This development is particularly relevant to the field of
pediatric hypertension, where long-term pharmacologic
interventions with agents that combine excellent efficacy
with a low side effect profile are required. In children,
secondary hypertension is of renal origin in 85% of the
cases [1]. Some degree of chronic renal failure (CRF)
is often present in children with severe, persistent re-
nal hypertension. In adults with CRF, renin-angiotensin
system (RAS) antagonists have become pharmacother-
apeutics of first choice, not only due to their excellent
systemic antihypertensive properties, but also because of
their unique renoprotective potential. Because of their
preferential action on the efferent arteriolar tone, RAS
antagonists reduce intraglomerular pressure and protein-
uria. Moreover, angiotensin antagonism suppresses lo-
cal growth factor, cytokine and chemokine release, with
subsequent reduction of glomerular hypertrophy and
sclerosis, as well as tubulointerstitial inflammation and
fibrosis [2]. The renoprotective efficacy of RAS antag-
onists, which is in part independent of blood pressure,
has been demonstrated in animal models and adults
with various acquired nephropathies [3–9]. However, in
children, the spectrum of renal disorders causing CRF
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differs from adults, with a preponderance of hypo-
/dysplastic and hereditary kidney disease.
In order to establish whether angiotensin-converting
enzyme (ACE) inhibition and the level of blood pres-
sure control affect the rate of CRF progression also in
pediatric kidney disease, the ESCAPE trial, an inter-
national, randomized, five-year prospective study, has
been launched in 33 European pediatric nephrology cen-
ters. As part of this trial, almost 400 children received
a fixed dose of the ACE inhibitor ramipril for at least
6 months following a two-month washout period during
which any RAS antagonist pretreatment was discontin-
ued. The patients were followed bimonthly, and ambula-
tory blood pressure monitoring (ABPM) was performed
before and after 6 months of treatment. This largest
prospective assessment of an antihypertensive drug ever
performed in children permits the assessment of the an-
tihypertensive and antiproteinuric efficacy, as well as the
safety of ramipril in children.
METHODS
Study protocol
Thirty-three pediatric nephrology units in 13 European
countries collaborated in a prospective, investigator-
initiated clinical trial to study the Effect of Strict Blood
Pressure Control and ACE Inhibition on the Progression
of CRF in PEdiatric Patients (ESCAPE trial).
The study protocol was developed exclusively by the
participants, and data are collected and analyzed by the
study coordinators. Monitoring of the collected data was
performed by an independent clinical research organiza-
tion (Omnicare Clinical Research). Industry sponsorship
was confined to support of the investigator meetings.
Within this trial, children aged 3 to 18 years with CRF
and high normal or elevated blood pressure (BP) received
a fixed dose of the ACE inhibitor ramipril (6 mg/m2 body
surface area in tablets of 1.25, 2.5, or 5 mg as a single
morning dose) and were randomized to either conven-
tional or intensified BP targets, aiming for the 50th to
95th or below the 50th percentile of 24-hour mean arterial
pressure (MAP) for height and gender [10], respectively.
During five years of follow-up, office BP, glomerular fil-
tration rate (GFR), and proteinuria are checked every
two months, and ABPM is performed every six months.
The study participants opted for open administration of
ramipril because a comparative trial design using a con-
trol arm receiving placebo or non-RAS antagonist anti-
hypertensive medication was considered unethical in the
light of the established renoprotective efficacy of ACE in-
hibition in adult patients [7, 11]. The study protocol was
approved by the local ethical committees, and written in-
formed consent was obtained from the parents and assent
from the patients.
During the first six months of the study, the effect of
ramipril on BP and proteinuria was observed. Antihyper-
tensive therapy was modified only if office BP was below
the 5th or above the 95th percentile. Adaptation of treat-
ment according to the randomized BP targets starts with
the first ABPM profile after 6 months of ramipril ther-
apy. Here, we present the results of the first six months
of ramipril therapy, focusing on the antihypertensive and
antiproteinuric efficacy, as well as on the safety of the
drug in children.
Patients
Four hundred and sixty-six children aged 3 to 18 years
with mild to moderate CRF (initial GFR 15 to 80 mL/
min/1.73m2) and a 24-hour MAP greater than the 50th
percentile for height and/or receiving antihypertensive
medication were enrolled in a six-month run-in period.
In all patients on prevalent ACE inhibitor therapy, this
medication was discontinued at least two months before
the end of the run-in period. During this wash-out period,
blood pressure was controlled by home and casual BP
measurements and, if necessary, antihypertensive medi-
cation was adjusted by adding non-RAS antagonists to
maintain a blood pressure in the normal range.
At time of randomization 397 patients fulfilled the
inclusion criteria and were started on ramipril, 352 of
whom completed at least 6 months of treatment (Fig. 1,
Table 1).
Renal hypo-/dysplasia was the underlying kidney dis-
order in 70%, acquired glomerulopathies in 13%, and
hereditary or other kidney diseases in 17% of the
patients.
Sixty-four percent of the patients had no antihyper-
tensive medication at baseline, 22% were on antihyper-
tensive monotherapy, and 14% were on two or more
antihypertensive drugs. Antihypertensive therapy at
baseline included calcium channel blockers (25%), beta-
(17%) or alpha-adrenergic blockers (5%), diuretics
(11%), centrally active and vasodilating agents (1%
each). Mean 24-hour systolic BP at baseline was elevated
to 118.8 mm Hg and diastolic BP to 73.3 mm Hg (+0.9 and
+1.1 SDS, respectively). At baseline, 24-hour MAP was
above the 95th percentile in 34%, between the 50th and
95th percentile in 39% and below the 50th percentile in
27% of patients. All patients with baseline 24-hour MAP
below the 50th percentile were on prevalent antihyper-
tensive medication.
Mean 24 hour heart rate was 83 bpm [i.e., in the mid-
normal range (0.0 standard deviation scores)].
The decision whether concomitant antihypertensive
medication was reduced, unchanged, or increased around
the time of randomization and start of ramipril was at the
discretion of the responsible physician. For the analysis of
the BP lowering effect of ramipril, patients were classi-
fied post-hoc into four groups according to the change
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466 pts screened
397 pts start of ramipril
Group A   214 pts
ramipril added,
no prevalent 
AHT
Group B     44 pts
ramipril added,
prevalent AHT
unchanged
Group C          72 pts
ramipril added,
prevalent AHT
reduced or exchanged
Group D     22 pts
ramipril added,
additional AHT
added
352 pts with ramipril treatment ≥6 months
45 pts drop out/withdrawal during first 6
treatment months (11.3%)
69 pts drop out/exclusion during run-in (14.8%)
Fig. 1. Study flow chart. AHT, antihyperten-
sive treatment; pts, patients.
in antihypertensive treatment regimen at introduction
of ramipril. Ramipril was instituted as the first antihy-
pertensive agent in group A (N = 214), or added to
an unchanged preexisting antihypertensive medication in
group B (N = 44). In group C (N = 72), the previous an-
tihypertensive medication was discontinued or reduced
at start of ramipril treatment. In group D (N = 22), ad-
ditional antihypertensive medication was prescribed at
or within two months after start of ramipril. Fifty-nine
percent of patients in group B received one, 41% two
or more antihypertensive agents at baseline. In group C,
all patients were on antihypertensive medication at base-
line, and 31% had at least two antihypertensive drugs.
In group D, 50% were without antihypertensive treat-
ment, 27% on monotherapy, and 23% on at least two
antihypertensive drugs at baseline. A higher proportion
of patients with glomerulopathies was present in group
D (32%) than in groups A (9%), B (18%), or C (13%).
Blood pressure monitoring
ABPM was performed with a Spacelabs 90207 au-
tomatic cuff-oscillometric device (Spacelabs Medical,
Issaquah, WA, USA) at screening, at the start, and six
months after start of ramipril. The cuff size was adjusted
to the upper arm circumference. ABPM measurements
were performed every 15 minutes during the daytime, and
every 20 to 30 minutes at night. All ABPM profiles were
analyzed centrally. ABPM profiles were divided into day-
time (08.00 to 20.00 hours) and nighttime periods (24.00
to 06.00 hours).
Office BP measurements were obtained using aus-
cultatory or oscillometric techniques at the bimonthly
outpatient visits after sitting for 5 minutes in a relaxed
position.
Laboratory assessments
Serum and urinary creatinine and sodium, as well as
urinary protein concentrations were measured centrally
Table 1. Baseline clinical characteristics of study cohort prior to
ramipril treatment (N = 352)
Mean ± SD Range
Age years 11.4 ± 4.0 3.5–18
Height cm 140.6 ± 22.4 89–190
Height SDS −0.9 ± 1.5 −6.8–2.9
Weight kg 38.0 ± 17.4 9–102
BMI kg/m2 18.1 ± 3.7 11.3–33.3
BMI SDS −0.01 ± 1.3 −4.6–3.2
24-hour systolic BP mm Hg 118.8 ± 11.4 91–169
24-hour systolic BP SDS 0.9 ± 1.4 −3.3–7.9
24-hour diastolic BP mm Hg 73.3 ± 9.3 57–119
24-hour diastolic BP SDS 1.1 ± 1.7 −2.2–9.8
24-hour MAP mm Hg 89.1 ± 9.6 69–135
24-hour MAP SDS 1.5 ± 1.9 −2.0–16.2
Urinary protein/creatinine ratio mg/mg 1.38 ± 1.88 0.0–15.8
Fractional sodium excretion % 2.4 ± 2.0 0.3–11.3
Creatinine clearance mL/min/1.73m2 47.6 ± 18.4 10.2–80.0
Patients in K/DOQI CKD [33] –/28/52/18/2
stage 1/2/3/4/5 %
in parallel to local analyses. The central measurements
of urinary protein excretion were performed using the
Coumassie method, and those of serum and urinary cre-
atinine by a modified Jaffe´ reaction. Serum and urinary
electrolytes, serum protein, and liver enzymes, as well
as blood cell counts were measured by standard labora-
tory techniques. In order to avoid artifacts due to sam-
pling errors in 24-hour urine collections, proteinuria was
expressed by the protein-creatinine ratio in the avail-
able urine samples (69% 24-hour urine collections, 31%
morning spot urine samples). Sodium excretion was ex-
pressed by the fractional excretion rate. Creatinine clear-
ance was estimated from serum creatinine and height
was estimated using the published pediatric equations
by Schwartz et al [12] as recommended by the K/DOQI
CKD guidelines [13]. Estimated creatinine clearance was
used to express GFR in the results section.
Statistical analysis
ABPM data were analyzed using the Spacelabs ABPM
Report Management System. All data was stored and
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processed with the SAS software (SAS Institute, Cary,
NC, USA). Blood pressure standard deviation scores
(SDS) were calculated using European ABPM reference
data [14]. Dipping was defined as a nocturnal decrease of
BP by more than 10% compared with mean daytime BP.
The Shapiro-Wilk test was used to test for normal distri-
bution. Urinary protein excretion parameters that were
not normally distributed were log-transformed for fur-
ther analysis. The longitudinal changes in blood pres-
sure and safety parameters (bimonthly assessments)
were evaluated by repeated-measure analysis of variance
(ANOVA) including a within-subject factor (time) and a
between-subject factor (e.g., different antihypertensive
treatment groups). Pairwise comparisons between differ-
ent time points and baseline were performed using the
CONTRAST option of the general linear models proce-
dure in the SAS software. For those parameters assessed
only at start and after 6 months (ABPM data), paired
Student t tests with a Bonferroni correction for multiple
testing were applied.
For multivariate analysis the following variables were
offered to the model: baseline creatinine clearance, base-
line MAP SDS, age, gender, number of antihypertensive
drugs at baseline, and underlying nephropathy (acquired
vs. congenital). In addition, baseline proteinuria was of-
fered to the model predicting the change of proteinuria.
Correlation coefficients were calculated using Spear-
man rank order correlation. P values of less than 0.05
were considered significant. All results are expressed as
mean ± SD.
RESULTS
Blood pressure response
After six months of ramipril treatment, mean 24-hour
MAP was reduced by 7.1 ± 8.0 mm Hg (i.e., by 1.3 ± 1.5
SDS) in the total cohort of 352 patients. The antihyper-
tensive effect was equally marked for systolic and dias-
tolic BP and for daytime and nighttime measurements
(Table 2), with an unchanged fraction of nocturnal
nondippers (at baseline 53 vs. 54% for systolic, 26 vs.
27% for diastolic BP at baseline and after 6 months, re-
spectively). The bimonthly office BP assessments fully
reflected the antihypertensive effect after two months
of treatment (Table 3). Notably, whereas BP was signifi-
cantly lower at baseline and after six months in group A
compared with the other groups (P < 0.05), the BP re-
sponse did not differ significantly between patients with
no (group A), unchanged (group B), reduced (group C),
or increased (group D) antihypertensive comedication
(Table 2). The BP lowering effect of ramipril was in-
dependent of gender. Moreover, while baseline BP was
significantly higher in patients with glomerulopathies
compared with children with renal hypo-/dysplasia and
hereditary or other kidney diseases, 24-hour MAP was
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Table 3. Effect of ramipril on office BP, serum and urine biochemistry, and blood cell counts in the total study population
Baseline 2 months 4 months 6 months
Office systolic BP mm Hg 117.5 ± 14.0 109.8 ± 15.4b 108.4 ± 15.6b 109.7 ± 14.4b
Office diastolic BP mm Hg 72.9 ± 11.8 65.1 ± 12.6b 65.2 ± 12.6b 65.4 ± 12.3b
Urinary protein/creatinine ratio mg/mg 1.38 ± 1.88 0.88 ± 1.46b 0.80 ± 1.19b 0.77 ± 1.11b
24-hour urinary protein excretion mg/m2/day 1003 ± 1703 497 ± 869b 506 ± 913b 522 ± 902b
Estimated creatinine clearance mL/min/1.73m2 47.6 ± 19.5 45.8 ± 19.8 44.8 ± 20.3a 44.2 ± 20.0b
Fractional sodium excretion % 2.4 ± 2.0 2.7 ± 2.3 3.0 ± 3.2 2.9 ± 2.9
Serum potassium mmol/L 4.3 ± 0.5 4.6 ± 0.6b 4.6 ± 0.6b 4.5 ± 0.8a
Hemoglobin level g/dL 12.2 ± 1.6 11.6 ± 1.8b 11.4 ± 1.8b 11.6 ± 1.8b
Blood leukocyte count T/lL 6.9 ± 1.8 6.8 ± 1.9 6.7 ± 2.0 6.8 ± 2.0
Thrombocyte count T/lL 260 ± 73 250 ± 76b 254 ± 71a 253 ± 73
Albumin g/L 42.0 ± 4.9 – – 42.3 ± 5.7a
Mean ± SD. Significant difference vs. baseline.
aP < 0.05; bP < 0.005.
reduced regardless of the underlying disease (Fig. 2). The
BP response was also independent of individual varia-
tions of the ramipril dose administered (applied dose 5.2
± 1.4 mg/m2/day).
Patients with baseline MAP greater than the 95th per-
centile (N = 119) had a significantly better response to
ramipril [MAP change −11.5 ± 8.7 mm Hg (i.e., −2.2 ±
1.8 SDS)] compared to patients with MAP below the 95th
percentile [ −4.4 ± 6.2 mm Hg (i.e. −0.8 ± 1.1 SDS), P <
0.0001]. After 6 months, 56% of all patients had achieved
a MAP below the 50th percentile; in 29 patients (9.3%)
24-hour MAP dropped below the 5th percentile. Never-
theless in only 2 patients was symptomatic hypotension
reported. In 12.7% of all patients blood pressure was still
above the 95th percentile. No patient was withdrawn from
the study due to non-response. In the initially hyperten-
sive patients MAP was below the 95th percentile in 65%.
Univariate regression analysis confirmed a linear rela-
tionship between baseline 24-hour MAP and its subse-
quent reduction during ramipril therapy (r = −0.51, P <
0.0001; Fig. 3). While no mean change in BP occurred
when baseline MAP was below 80 mm Hg, MAP was re-
duced on average by 5.2 mm Hg with every 10 mm Hg
baseline MAP above 80.
The change in 24-hour MAP was significantly greater
in patients with a residual GFR <40 mL/min/1.73 m2
(−1.7 ± 1.6 SDS) than in patients with better renal func-
tion (−1.1 ± 1.4 SDS, P < 0.005), and GFR was weakly in-
versely related to the blood pressure response (r = −0.17,
P < 0.01). Furthermore, the change in 24-hour MAP SDS
was positively correlated with the degree of proteinuria
(r = 0.25; P < 0.0001) and fractional sodium excretion
at baseline (r = 0.20, P < 0.001). The antihypertensive
response was significantly greater in patients with gross
proteinuria (urinary protein/creatinine ratio >1) (change
in MAP −1.8 ± 1.8 SDS) than in children with mild or no
proteinuria (−1.0 ± 1.4 SDS; P < 0.0005). Patient age was
marginally inversely correlated with the antihypertensive
response to ramipril (r = −0.12, P < 0.05).
Multivariate regression analysis revealed that the
change in 24-hour MAP SDS in the total cohort was in-
P < 0.001
P < 0.0001
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Fig. 2. Change of 24-hour MAP SDS according to underlying renal
disease. Bars represent mean ± SEM.
dependently predicted by baseline MAP SDS (positive
effect, partial r2 = 0.395, P < 0.0001), the number of con-
comitant antihypertensive drugs at baseline (negative ef-
fect, partial r2 = 0.022, P < 0.005), gender (male>female,
partial r2 = 0.012, P < 0.05), age (negative effect, partial
r2 = 0.01, P < 0.05), and baseline proteinuria (positive
effect, partial r2 = 0.017, P < 0.01). When only those pa-
tients were considered in whom the addition of ramipril
was the only pharmacologic intervention during the study
period (groups A and B), baseline MAP SDS (positive ef-
fect, partial r2 = 0.37, P < 0.0001), GFR (negative effect,
partial r2 = 0.044, P < 0.001), age (negative effect, partial
r2 = 0.023, P < 0.01), gender (male>female, partial r2 =
0.014, P < 0.05), and the number of concomitant antihy-
pertensive drugs (negative effect, partial r2 = 0.014, P <
0.05) emerged as independent predictors of the change
in 24-hour MAP SDS.
In the subgroup of patients with manifest hyperten-
sion (MAP at baseline >95th percentile) baseline MAP
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r = –0.51
P < 0.0001
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Fig. 3. Correlation between baseline 24-hour MAP and change of 24-
hour MAP during ramipril treatment.
SDS (r2 = 0.37, P < 0.0001) remained the only important
predictor of the antihypertensive effect of ramipril.
Antiproteinuric response
Ramipril reduced urinary protein excretion by ap-
proximately 50% within the first six treatment months
(Table 3). The antiproteinuric effect of ramipril depended
on baseline proteinuria (r = 0.32, P < 0.0001), and was
weakly inversely correlated to age (r = −0.12, P < 0.05).
Moreover, the antiproteinuric response to ramipril was
associated with the blood pressure-lowering effect of the
drug (r = 0.22, P < 0.001).
While patients with glomerulopathies had significantly
greater proteinuria both at baseline (2.93 ± 3.53 mg/mg)
and after 6 treatment months (1.66 ± 2.80 mg/mg)
than children with renal hypo/dysplasia (baseline: 1.12 ±
1.42 mg/mg, 6 months: 0.67 ± 0.91 mg/mg) and hereditary
or other kidney disorders (baseline: 1.07 ± 1.71 mg/mg,
6 months: 0.54 ± 0.95 mg/mg), the relative antiprotein-
uric effect of ramipril was independent of the underlying
nephropathy. Also, the antiproteinuric response did not
differ between patients who received additionally either
a Ca-channel blocker, a b-blocker, or no antihypertensive
medication.
In the total cohort, the change in protein excretion was
independently predicted by baseline proteinuria (posi-
tive effect, partial r2 = 0.14, P < 0.0001), baseline GFR
(positive effect, partial r2 = 0.037, P < 0.0001), gender
Table 4. Reasons for withdrawal from the study during the run-in
and the treatment period (duration 6 months each)
Pretreatment run-in Treatment
period (N = 466) period (N = 397)
Inclusion criteria not fulfilled 32 (6.7%) –
Increase of serum creatinine 4 (0.9%) 5 (1.3%)
Start of renal 8 (1.7%) 7 (1.8%)
replacement therapy
Hypotension – 2 (0.5%)
Hyperkalemia – 1 (0.3%)
Cough – 1 (0.3%)
Noncompliance 8 (1.7%) 2 (0.5%)
Patient’s request 8 (1.7%) 2 (0.5%)
Loss of follow-up 8 (1.3%) 25 (6.3%)
Others 3 (0.6%) –
Total 69 (14.8%) 45 (11.3%)
(male>female, partial r2 = 0.027, P < 0.005), and age
(negative effect, partial r2 = 0.018, P < 0.05).
As a possible effect of the antiproteinuric action of
ramipril, serum albumin levels increased slightly but
significantly within six months of ramipril treatment
(Table 3).
Adverse effects
Acute impairment of renal function has been reported
in CRF patients receiving ACE inhibitors. A decline
in calculated creatinine clearance by greater than 25%
within any two-month interval was defined as the limit
at which ramipril had to be discontinued. Ramipril was
discontinued in five of 397 patients during the first six
treatment months due to an acute GFR loss. Ramipril
was successfully restarted in two of these five patients
after several weeks. Seven patients started renal replace-
ment therapy during the six-month observation period.
An analysis of the rate of GFR loss before and after ini-
tiation of ramipril (linear regression analysis of GFR loss
before and after start of treatment) indicated that in only
one of these subjects was an accelerated deterioration
of renal function associated with ramipril administration.
The incidence of these events was similar to the six-month
pretreatment run-in period (Table 4). In those patients
who continued to receive ramipril for six months, GFR
slowly decreased over time, becoming significantly differ-
ent relative to baseline after four months (Table 3).
Serum potassium levels increased within two months
of treatment by an average of 0.3 mmol/L (P < 0.0001,
Table 3). A single patient was withdrawn from the study
due to hyperkalemia (Table 4). The use of anion exchange
resin did not change (3% of patients both before and
during ramipril). Mean hemoglobin levels decreased by
0.6 g/dL within two months of treatment and remained
stable thereafter (Table 3). In addition, the fraction of
children requiring erythropoietin therapy increased from
6.1% to 10.5% within 6 months. This compared to sta-
ble hemoglobin levels in the pretreatment run-in period
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(mean 12.1 ± 1.7 g/dL at screening, rate of change +
0.1 ± 1.2 g/dL during 6 months run-in period, fraction
of EPO treated patients 5.5%). Platelet counts showed a
transient slight decrease within the first four months of
treatment but had recovered at six months. Leukocyte
counts did not change significantly. No withdrawal from
the study due to anemia, leukocytopenia, or thrombocy-
topenia was reported.
Notably, the changes in GFR, potassium, and
hemoglobin levels were significantly correlated with the
antihypertensive efficacy of ramipril. Those patients with
a greater blood pressure response also tended to have a
more marked drop of hemoglobin levels (r = 0.25, P <
0.0001), a greater increase of serum potassium (r =−0.29,
P < 0.0001), and a marginally larger decline of GFR (r =
0.11, P < 0.05).
DISCUSSION
This analysis describes the blood pressure–lowering,
antiproteinuric, and adverse effects of a fixed dose of
ramipril administered in almost 400 children with CRF
and elevated or high normal blood pressure in the ini-
tial controlled intervention phase of the ESCAPE trial.
The blood pressure response was strictly dependent on
the prevailing blood pressure level, and the antiprotein-
uric response on the prevailing degree of proteinuria.
The efficacy of ramipril was independent of the under-
lying renal disease, but slightly greater in patients with
advanced CRF. Boys tended to respond better than girls
and younger children better than older ones. Ramipril
was well tolerated; in only 2.4% of patients was the drug
withdrawn due to adverse effects.
In the children with manifest hypertension at start of
treatment, MAP was lowered by an average of 11.6 mm
Hg, shifting 65% of the initially hypertensive patients into
the normal range. This level of antihypertensive efficacy
was comparable to recent pediatric studies using ACE
inhibitors [15, 16] or angiotensin II receptor antagonists
[17–19], and superior to results reported with calcium
channel blockers (amlodipine, felodipine) [20, 21] and
b-blockers [22]. The relative inefficiency of non-RAS an-
tagonists in controlling renal hypertension is underlined
by the fact that 45% of the patients who entered the
study with manifest hypertension were already receiving
calcium channel blockers, and 20% were receiving beta
blockers. Moreover, the overall blood pressure response
in patients in whom concomitant antihypertensive med-
ication was either reduced or increased around the start
of ramipril (groups C and D) was not different from that
observed when only ramipril was added (groups A and
B), lending further support to the notion that angiotensin
inhibition is a superior antihypertensive strategy in chil-
dren with CRF.
Ramipril reduced blood pressure as efficiently in re-
nal hypo-/dysplasia and hereditary kidney disorders as in
acquired glomerulopathies, suggesting that children with
CRF-associated hypertension will benefit from ACE in-
hibition regardless of their underlying disease.
Moreover, the use of ABPM permitted us to demon-
strate that a single morning dose of ramipril provided
equally good control of MAP during day- and nighttime.
However, blood pressure was not completely normal-
ized in patients with very severe hypertension, particu-
larly in children with glomerulopathies. A fixed ramipril
dose (6 mg/m2) was prescribed that was four times higher
than the dose validated in the only clinical trial performed
with ramipril in children to date [15]. We cannot exclude
that an even higher dose might have yielded a still greater
antihypertensive effect. A recent pediatric trial using the
ACE inhibitor enalapril showed little dose dependency
between 0.625 and 2.5 mg, but an almost doubled antihy-
pertensive effect when the dose was increased from 2.5
to 20 mg [16]. Correspondingly, the full antihypertensive
potential of ramipril may not have been exploited in in-
dividual patients in this trial.
The ESCAPE trial is not limited to hypertensive CRF
patients, but also investigates the renoprotective efficacy
of ACE inhibition and intensified blood pressure control
in children with high normal blood pressure. This pro-
vided the opportunity to study the effect of ramipril in a
wide range of baseline blood pressure. Interestingly, the
blood pressure response to ramipril was closely related
to the blood pressure level at baseline. Blood pressure
was reduced on average by 20 mm Hg when baseline 24-
hour MAP was 120 mm Hg, but did not change when
the prevailing MAP was 80 mm Hg or less. Symptomatic
hypotension was observed in only two out of almost 400
children. A lack of blood pressure lowering effect in nor-
motensive patients has also been observed with other
RAS antagonists in children [18, 19], and a relationship
between baseline blood pressure and the blood pressure
response has also been found with a beta-blocker/thiazide
combination [22].
The change in 24-hour MAP tended to be more marked
in patients with a GFR less than 40 mL/min/1.73 m2.
Albeit weak, this effect appeared independent of the
prevailing degree of hypertension in the multivariate
analysis. In addition, the degree of initial proteinuria was
a positive predictor of the antihypertensive efficacy of
ramipril, which is compatible with the interpretation that
ramipril was most effective in children with a high in-
trarenal angiotensin tone and glomerular hypertension.
Because proteinuria is an important risk factor for dis-
ease progression, which is independent of blood pres-
sure in adults [23] and children with CRF [24], we were
particularly interested in the antiproteinuric efficacy of
ramipril treatment. We observed an average reduction of
proteinuria by approximately 50%, in keeping with other
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pediatric trials using RAS antagonists [15, 17–19, 25,
26], and equivalent to the effect observed in adult
nephropathies [27–29]. Notably, children with hypo/
dysplastic renal disorders responded with a similar rel-
ative proteinuria reduction as patients with acquired
glomerulopathies. Also, the degree of proteinuria at base-
line was correlated with the relative antiproteinuric effect
of ramipril, again suggesting that the drug was partic-
ularly efficacious in patients with a more marked renal
disease activity. As for blood pressure, we do not know
whether higher dosing of ramipril would have been more
efficacious in lowering proteinuria; however, a study in 14
proteinuric children using only one quarter of the dose
applied here reported a similar antiproteinuric effect [15].
Although ramipril was administered at a relatively high
dose, remarkably few side effects occurred in the first
six months of treatment. The observed mean increase of
serum potassium by 0.3 mmol/L compared favorably with
values reported in adults (0.3 to 0.6 mmol/L) [3, 4, 30].
Ramipril had to be discontinued because of persistent
hyperkalemia only in a single patient (0.3%), compared
with 1.2% to 1.6% in adult trials.
Five patients were withdrawn from the study due to
an accelerated increase of serum creatinine, and seven
patients reached the end point of renal replacement ther-
apy. The incidence of these events was identical to the
pretreatment period.
ACE inhibitors are known to interfere with hema-
topoiesis [31]. In our study, administration of ramipril
was associated with a drop in mean hemoglobin levels by
0.6 g/dL within two months. Erythrocyte counts stabilized
during further follow-up, but the fraction of patients re-
quiring erythropoietin supplementation was nearly dou-
bled compared to the pretreatment phase.
Dry cough is a frequently reported side effect of ACE
inhibition in adults (5% to 39%) [32]. Remarkably, no
increased incidence of cough was reported in our patients,
and only a single patient was withdrawn due to persistent
dry cough (0.3%).
CONCLUSION
Ramipril appears to be an effective blood pressure low-
ering and antiproteinuric agent in children with CRF. The
magnitude of the antihypertensive effect depends on the
degree of blood pressure elevation at baseline, and the
antiproteinuric effect on the prevailing level of protein-
uria. The safety profile of the drug in children appears
to be good. The continued trial will delineate the reno-
protective efficacy of ACE inhibition in pediatric kidney
diseases.
APPENDIX
ESCAPE trial participants are as follows: A. Anarat (Adana); A.
Bakkaloglu, F. Ozaltin (Ankara); A. Peco-Antic (Belgrade); U. Quer-
feld, J. Gellermann (Berlin); P. Sallay (Budapest); D. Drozdz (Cracow);
K.-E. Bonzel, A.-M. Wingen (Essen); A. Zurowska, I. Balasz (Gdansk);
F. Perfumo, A. Canepa (Genoa); D.E. Mu¨ller-Wiefel, K. Zepf (Ham-
burg); G. Offner, B. Enke (Hannover); O. Mehls, F. Schaefer, E. Wu¨hl,
C. Hadtstein (Heidelberg); U. Berg, G. Celsi (Huddinge); S. Emre, A.
Sirin, I. Bilge (Istanbul); S. C¸aliskan (Istanbul-Cerrahpasa); S. Mir, E.
Serdaroglu (Izmir); C. Greiner, H. Eichsta¨dt, S. Wygoda (Leipzig); K.
Hohbach-Hohenfellner (Mainz); N. Jeck, G. Klaus (Marburg); A. Ap-
piani, G. Ardissino, S. Testa (Milano); G. Montini (Padova); P. Niaudet,
M. Charbit (Paris); J. Dusek (Prague); A. Caldas-Afonso, A. Teixeira
(Porto); S. Picca, C. Matteucci (Rome); M. Wigger (Rostock); M. Fis-
chbach, J. Terzic (Strasbourg); J. Fydryk, T. Urasinski (Szezecin); R.
Coppo, L. Peruzzi (Torino); A. Jankauskiene (Vilnius); M. Litwin, M.
Abuauba, R. Grenda (Warszawa); K. Arbeiter (Vienna); T.J. Neuhaus
(Zurich).
ACKNOWLEDGMENT
Support for this study was obtained from the European Commission
(5th Framework Programme, QLG1-CT-2002–00908), the Boehringer
Ingelheim Foundation, the Baxter Extramural Grant Program, and
Aventis Pharma.
Reprint requests to Dr. Franz Schaefer, University Children’s Hospital,
Im Neuenheimer Feld 151, 69120 Heidelberg, Germany.
E-mail: franz schaefer@med.uni-heidelberg.de
REFERENCES
1. SCHA¨RER K: Hypertension in children and adolescents, chap 1-25, in
Clinical Nephrology, Dialysis and Transplantation: a continuously
updated textbook, edited by Malluche HH, Sawaya BP, Hakim RM,
Sayegh MH, Deisenhofen, Dustri-Verlag, 1999, pp 1–28
2. SCHAEFER F, MEHLS O: Hypertension in chronic kidney disease, in
Pediatric Hypertension, edited by Portman RJ, Sorof JM, Ingelfinger
JR, Totowa, N.J., Humana Press, 2003
3. MASCHIO G, ALBERTI D, JANIN G, et al: Effect of angiotensin-
converting-enzme inhibitor benazepril on the progression of
chronic renal insufficiency. N Engl J Med 334:939–945, 1996
4. THE GISEN GROUP (GRUPPO ITALIANO DI STUDI EPIDEMIOLOGICI
IN NEFROLOGIA): Randomised placebo-controlled trial of effect of
ramipril on decline in glomerular filtration rate and risk of termi-
nal renal failure in proteinuric, non-diabetic nephropathy. Lancet
349:1857–1863, 1997
5. PARVING HH, ANDERSEN AR, SMIDT UM, SVENDSEN PA: Early ag-
gressive antihypertensive treatment reduces rate of decline in kid-
ney function in diabetic nephropathy. Lancet 1:1175–1179, 1983
6. RUGGENENTI P, PERNA A, GHERARDI G, et al: Chronic proteinuric
nephropathies: Outcomes and response to treatment in a prospec-
tive cohort of 352 patients with different patterns of renal injury.
Am J Kidney Dis 35:1155–1165, 2000
7. JAFAR TH, SCHMID CH, LANDA M, et al: Angiotensin-converting
enzyme inhibitors and progression of nondiabetic renal disease. A
meta-analysis of patient-level data. Ann Intern Med 135:73–87, 2001
8. LEWIS EJ, HUNSICKER LG, RAYMOND PB, et al: The effect of
angiotensin-converting-enzyme inhibition on diabetic nephropathy.
N Engl J Med 329:1456–1462, 1993
9. KAMPER AL, STRANDGAARD S, LEYSSAC P: Effect of enalapril on the
progression of chronic renal failure: A randomized controlled trial.
Am J Hypertens 5:423–430, 1992
10. SOERGEL M, KIRSCHSTEIN M, BUSCH C, et al: Oscillometric twenty-
four-hour ambulatory blood pressure values in healthy children and
adolescents: A multicenter trial including 1141 subjects. J Pediatr
130:178–184, 1997
11. FLYNN JT: Ethics of placebo use in pediatric clinical trials: The
case of antihypertensive drug studies. Hypertension 42:865–869,
2003
12. SCHWARTZ GJ, BRION LP, SPITZER A: The use of plasma creati-
nine concentration for estimating glomerular filtration rate in in-
fants, children and adolescents. Pediatr Clin North Am 34:571–590,
1987
13. NATIONAL KIDNEY FOUNDATION: K/DOQI clinical practice guidelines
776 Wu¨hl et al: Ramipril in children with CRF
for chronic kidney disease: Evaluation, classification, stratification.
Part 5. Evaluation of laboratory measurements for clinical assess-
ment of kidney disease. Am J Kidney Dis 39(Suppl 1):S76–S110,
2002
14. WU¨HL E, WITTE K, SOERGEL M, et al: Distribution of 24-h ambulatory
blood pressure in children: Normalized reference values and role of
body dimensions. J Hypertens 20:1995–2007, 2002
15. SOERGEL M, VERHO M, WU¨HL E, et al: Effect of ramipril on ambula-
tory blood pressure and albuminuria in renal hypertension. Pediatr
Nephrol 15:113–118, 2000
16. WELLS T, FRAME V, SOFFER B, et al: A double-blind, placebo-
controlled, dose-response study of the effectiveness and safety of
enalapril for children with hypertension. J Clin Pharmacol 42:870–
880, 2002
17. VON VIGIER RO, ZBERG PM, TEUFFEL O, BIANCHETTI MG: Prelim-
inary experience with the angiotensin II receptor antagonist irbe-
sartan in chronic kidney disease. Eur J Pediatr 159:590–593, 2000
18. FRANSCINI LMD, VON VIGIER RO, PFISTER R, et al: Effectiveness and
safety of the angiotensin II antagonist irbesartan in children with
chronic kidney diseases. Am J Hypertens 15:1057–1063, 2002
19. ELLIS D, VATS A, MORITZ ML, et al: Long-term antiproteinuric and
renoprotective efficacy and safety of losartan in children with pro-
teinuria. J Pediatr 143:89–97, 2003
20. VON VIGIER RO, FRANSCINI LMD, BIANDA ND, et al: Antihyperten-
sive efficacy of amlodipine in children with chronic kidney diseases.
J Hum Hypertens 15:387–391, 2001
21. TRACHTMAN H, FRANK R, MAHAN JD, et al: Clinical trial of
extended-release felodipine in pediatric essential hypertension. Pe-
diatr Nephrol 15:548–553, 2003
22. SOROF JM, CARGO P, GRAEPEL J, et al: b-blocker/thiazide combina-
tion for treatment of hypertensive children: A randomized double-
blind, placebo-controlled trial. Pediatr Nephrol 17:345–350, 2003
23. JAFAR TH, STARK PC, SCHMID CH, et al: Progression of chronic kid-
ney disease: The role of blood pressure control, proteinuria, and
angiotensin-converting enzyme inhibition. A patient meta-analysis.
Ann Intern Med 139:244–252, 2003
24. WINGEN AM, FABIAN BACH C, SCHAEFER F, et al: Randomised mul-
ticentre study of a low-protein diet on the progression of chronic
renal failure in children. Lancet 349:1117–1123, 1997
25. GARTENMANN AC, FOSSALI E, VON VIGIER RO, et al: Better renopro-
tective effect of angiotensin II antagonist compared to dihydropy-
ridine calcium channel blocker in childhood. Kidney Int 64:1450–
1454, 2003
26. PROESMANS W, VAN WAMBEKE I, VAN DYCK M: Long term therapy
with enalapril in patients with nephrotic-range proteinuria. Pediatr
Nephrol 10:587–589, 1996
27. RUGGENENTI P, PERNA A, GHERARDI G, et al: Renoprotective prop-
erties of ACE-inhibition in non-diabetic nephropathies with non-
nephrotic proteinuria. Lancet 354:359–364, 1999
28. SHIIGAI T, SHICHIRI M: Late escape from the antiproteinuric effect
of ACE inhibitors in nondiabetic renal disease. Am J Kidney Dis
37:477–483, 2001
29. PISONI R, RUGGENENTI P, SANGALLI F, et al: Effect of high dose
ramipril with or without indomethacin on glomerular selectivity.
Kidney Int 62:1010–1019, 2002
30. BAKRIS GL, SIOMOS M, RICHARDSON D, et al: ACE inhibition or
angiotensin receptor blockade: Impact on potassium in renal failure.
Kidney Int 58:2084–2092, 2000
31. HAZNEDAROGLU IC, OZTURK MA: Towards the understanding of
the local hematopoietic bone marrow renin-angiotensin system. Int
J Biochem Cell Biol 6:867–880, 2003
32. SEBASTIAN JL, MCKINNEY WP, KAUFMANN J, YOUNG MJ:
Angiotensin-converting enzyme inhibitors and cough: Prevalence
in an outpatient medical clinic population. Chest 99:36–39, 1991
33. NATIONAL KIDNEY FOUNDATION: K/DOQI clinical practice guidelines
for chronic kidney disease: Evaluation, classification, stratification.
Part 4. Definition and classification of stages of chronic kidney dis-
ease. Am J Kidney Dis 39(Suppl 1):S46–S75, 2002
